Skip to content

Investigating the effect of melatonin in controlling migraine headaches in female patients

Investigating the effect of melatonin in controlling migraine headaches in female patients

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250115064392N1
Enrollment
80
Registered
2025-02-06
Start date
2025-02-08
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine headache. Migraine

Interventions

Intervention 1: Prolol and sodium valproate, melatonin 5 mg, daily. Intervention 2: Receiving a placebo, one tablet daily, for 3 months.

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women 18 to 45 The completeness of the file information and patient records Definitive diagnosis of migraine by a doctor Absence of secondary headache Not having any disease or comorbidity that can lead to headache or other migraine symptoms

Exclusion criteria

Exclusion criteria: Unwillingness to continue cooperation in any of the stages of the research Observing the serious side effects of melatonin

Design outcomes

Primary

MeasureTime frame
Severity of headache attacks. Timepoint: 0 to 10 days. Method of measurement: Patient statements.;Frequency of headache attacks. Timepoint: Number of headaches per month. Method of measurement: Patient statements.;Duration of headache. Timepoint: hour. Method of measurement: Patient statements.;Number of times painkillers were used. Timepoint: Number per week. Method of measurement: Patient statements.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMorteza Arbabi

Zahedan University of Medical Sciences

morteza24410@zaums.ac.ir+98 54 3351 3778

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026